Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

By Issa Jean-Pierre   Garcia-Manero Guillermo   Huang Xuelin   Cortes Jorge   Ravandi Farhad   Jabbour Elias   Borthakur Gautam   Brandt Mark   Pierce Sherry   Kantarjian Hagop M.  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 556-561

Blackwell Publishing

Access to resources Recommend Favorite

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-α Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

By Reed Shelby D.   Anstrom Kevin J.   Li Yanhong   Schulman Kevin A.  

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite

AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia

By Cooper Todd M.   Alonzo Todd A.   Gerbing Robert B.   Perentesis John P.   Whitlock James A.   Taub Jeffrey W.   Horton Terzah M.   Gamis Alan S.   Meshinchi Soheil   Loken Michael R.   Razzouk Bassem I.  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2482-2489

Blackwell Publishing

Access to resources Recommend Favorite

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

By Breccia Massimo   Alimena Giuliana  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2075-2087

Informa Healthcare

Access to resources Recommend Favorite

Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 110-115

John Wiley & Sons Inc

Access to resources Recommend Favorite